BRICANYL TURBOHALER 500 Mcg/Acutuation Powder for Inhalation
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
25-04-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
TERBUTALINE SULFATE
Available from:
LTT Pharma Limited
INN (International Name):
TERBUTALINE SULFATE
Dosage:
500 Mcg/Acutuation
Pharmaceutical form:
Powder for Inhalation
Prescription type:
Product subject to prescription which may be renewed (B)
Authorization status:
Withdrawn
Authorization date:
2013-03-05
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Bricanyl Turbohaler 500 micrograms per metered dose, inhalation powder.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each metered dose contains 500 micrograms Terbutaline Sulphate.
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Inhalation Powder.
_Product imported from the UK:_
Multi-dose breath-actuated metered dose powder inhaler. White to off-white spherical particles which break into a fine
powder on inhalation.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Terbutaline is a selective beta
2
-adrenergic agonist recommended for the relief and prevention of bronchospasm in
bronchial asthma and in chronic bronchitis and other bronchopulmonary disorders in which bronchospasm is a
complicating factor.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Adults and Children:
One inhalation (500 micrograms) (metered dose) as required. Not more than 4 inhalations should be necessary in any
24 hour period.
Elderly:
Dosage as for adults.
Instructions for use and cleaning are provided in the Patient Information Leaflet, which can be found in each pack.
4.3 CONTRAINDICATIONS
Bricanyl preparations are contra-indicated in patients with a history of sensitivity to terbutaline sulphate.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Patients should be instructed in proper use and their inhalation technique checked regularly.
With each inhalation a fraction of the delivered dose will be deposited in the oral cavity. To minimize unnecessary
systemic exposure to terbutaline, the patients should be advised to, when possible, rinse their mouth after each use.
If a previously effective dosage regimen no longer gives the same symptomatic relief, the patient should urgently seek
further medical advice. Consideration should be given
Read the complete document
